Last reviewed · How we verify
Rebif® (clone 484-39)
Rebif® (clone 484-39) is a Interferon beta-1a Biologic drug developed by Merck KGaA, Darmstadt, Germany. It is currently FDA-approved for Relapsing-remitting multiple sclerosis (RRMS), Clinically isolated syndrome (CIS) with high risk of developing MS. Also known as: Recombinant-human interferon beta-1a, r-hIFN Beta-1a.
Rebif is an interferon beta-1a that activates interferon receptors on immune cells to modulate immune response and reduce inflammation in the central nervous system.
Rebif (clone 484-39) is a medication used to treat Relapsing Remitting Multiple Sclerosis. It is a recombinant human interferon beta-1a, administered subcutaneously.
At a glance
| Generic name | Rebif® (clone 484-39) |
|---|---|
| Also known as | Recombinant-human interferon beta-1a, r-hIFN Beta-1a |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Interferon beta-1a |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Immunology / Neurology |
| Phase | FDA-approved |
Mechanism of action
Interferon beta-1a binds to type I interferon receptors (IFNAR1/IFNAR2) on the surface of immune cells and oligodendrocytes, triggering intracellular signaling cascades that increase expression of anti-inflammatory genes and decrease pro-inflammatory cytokine production. This leads to reduced migration of immune cells across the blood-brain barrier and decreased demyelination in multiple sclerosis. The mechanism also includes upregulation of immunoregulatory factors and suppression of Th1 and Th17 cell differentiation.
Approved indications
- Relapsing-remitting multiple sclerosis (RRMS)
- Clinically isolated syndrome (CIS) with high risk of developing MS
Common side effects
- Injection site reactions
- Flu-like symptoms (fever, chills, myalgia)
- Headache
- Fatigue
- Depression
- Elevated liver enzymes
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebif® (clone 484-39) CI brief — competitive landscape report
- Rebif® (clone 484-39) updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI
Frequently asked questions about Rebif® (clone 484-39)
What is Rebif® (clone 484-39)?
How does Rebif® (clone 484-39) work?
What is Rebif® (clone 484-39) used for?
Who makes Rebif® (clone 484-39)?
Is Rebif® (clone 484-39) also known as anything else?
What drug class is Rebif® (clone 484-39) in?
What development phase is Rebif® (clone 484-39) in?
What are the side effects of Rebif® (clone 484-39)?
What does Rebif® (clone 484-39) target?
Related
- Drug class: All Interferon beta-1a drugs
- Target: All drugs targeting Type I interferon receptor (IFNAR)
- Manufacturer: Merck KGaA, Darmstadt, Germany — full pipeline
- Therapeutic area: All drugs in Immunology / Neurology
- Indication: Drugs for Relapsing-remitting multiple sclerosis (RRMS)
- Indication: Drugs for Clinically isolated syndrome (CIS) with high risk of developing MS
- Also known as: Recombinant-human interferon beta-1a, r-hIFN Beta-1a
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing